AbCheck adds antibody affinity maturation and developability optimization to its unique Phage and Yeast Display technologies
(Thomson Reuters ONE) -
AbCheck s.r.o. /
AbCheck adds antibody affinity maturation and developability optimization to its
unique Phage and Yeast Display technologies
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
New technology delivers high quality antibodies through unique technology
combinations
Plzen, Czech Republic; November 13, 2012: AbCheck s.r.o., the multi antibody
discovery platforms company, announced today the company has licensed a
proprietary affinity maturation and optimization technology from Distributed Bio
LLC (San Francisco, CA, USA). Under the exclusive, worldwide agreement AbCheck
will apply the proprietary computational library design algorithms to address
the affinity maturation, therapeutic developability and stability optimization
of antibodies in a single one-step process. The addition of this platform to
AbCheck's current phage display antibody libraries and Yeast platforms places
the company in a unique position to deliver functional, "GMP ready", developable
antibodies with significantly increased affinities with minimal mutations from
fully human frameworks.
"Not only from a technological standpoint but also from a commercial point of
view this partnership between Distributed Bio and AbCheck is a perfect synergy,"
said Dr. Volker Lang, CEO of AbCheck. "By combining the strength of both
technologies we have created a platform that exactly addresses current market
needs. Moreover, we can combine this with delivery in very competitive
timeframes and maximum flexibility to construct tailor made deals with favorable
terms."
"Library design algorithms redefine the full potential of high throughput
screening," said Jacob Glanville, Scientific Director of Distributed Bio.
"Between affinity maturation, germlining, humanization, stabilization,
biochemical liability elimination, immunogenicity minimization, and cross-
reactivity modulation, antibody bioengineering has historically been a very time
consuming, iterative process. However, decades of global antibody engineering
research, combined with the awesome power of next generation sequencing
technologies, have given us sophisticated rule sets that dictate the successful
construction of biologic medicines. Distributed Bio's library design algorithms
encode years of protein bioengineering directly into the library designs. We are
delighted to bring this technology forward with AbCheck: their leading edge
expertise in antibody engineering and library development make them an ideal
partner for introducing this new technology to the market.
About AbCheck
AbCheck s.r.o. focuses on the discovery and/or optimization of human antibodies
for partner companies. AbSieve, the combined phage and yeast display platforms,
is used to develop antibodies in all antibody formats including full length IgGs
as well as customer specific and novel antibody formats. AbAccel, a proprietary
algorithm for affinity maturation and optimization, is combined with Phage or
Yeast Display and addresses affinity maturation, developability and stability
optimization of antibodies in just one step. Antibodies generated by AbCheck's
AbSieve and AbAccel platforms have extremely high specificities and affinities,
they are "GMP ready" and have improved drugability. Furthermore, the use of
Yeast display allows the screening in the final antibody drug format. AbCheck
has entered into several partnerships and is recognized for its expertise in
antibody discovery throughout the US and Europe.
About Distributed Bio
Distributed Bio is a fully integrated bioinformatics services company
specializing in the support of genomic technologies such as NextGen sequencing,
antibody informatics and computational bioengineering. By combining unique
expertise in computational biology algorithm development with leading
technological expertise in data life cycle management, Web2.0 development, high
performance, cloud and distributed computing, Distributed Bio licenses, hosts or
deploys technologies that massively accelerate biotechnology research. Deployed
Distributed Bio solutions have integrated antibody library designs, novel
analysis algorithms and platforms, high-performance computing and data
infrastructure to produce a complete value chain. The solutions can be hosted
on internal client systems, virtually on cloud platforms, or bursting to cloud
in hybrid environments. Clients that use Distributed Bio solutions overcome the
bioinformatics bottleneck: delivering novel scientific insights faster with
little or no infrastructure costs.
For further information please contact:
AbCheck s.r.o. Distributed Bio
Dr. Volker Lang Giles Day
Managing Director Managing Director
Phone: +420 378 051500 Phone: +1 415 489 0246
Fax: +420 378 051506 Email: press(at)distributedbio.com
Email: V.Lang(at)abcheck.eu
MC Services AG
Anne Hennecke
Managing Partner
Phone: +49 89 210 228 18
Fax: +49 89 210 228 88
Email: anne.hennecke(at)mc-services.eu
Press Release (PDF):
http://hugin.info/143842/R/1657232/535967.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: AbCheck s.r.o. via Thomson Reuters ONE
[HUG#1657232]
Unternehmensinformation / Kurzprofil:
Datum: 13.11.2012 - 09:30 Uhr
Sprache: Deutsch
News-ID 202527
Anzahl Zeichen: 6435
contact information:
Town:
Plzen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 139 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"AbCheck adds antibody affinity maturation and developability optimization to its unique Phage and Yeast Display technologies"
steht unter der journalistisch-redaktionellen Verantwortung von
AbCheck s.r.o. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
